{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T16:00:19Z","timestamp":1775318419231,"version":"3.50.1"},"reference-count":146,"publisher":"Georg Thieme Verlag KG","issue":"11","license":[{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Waldenstr\u00f6m macroglobulinemia (WM) is a rare, incurable, low-grade, B cell lymphoma. Symptomatic disease commonly results from marrow or organ infiltration and hyperviscosity secondary to immunoglobulin M paraprotein, manifesting as anemia, bleeding and neurological symptoms among others. The causes of the bleeding phenotype in WM are complex and involve several intersecting mechanisms. Evidence of defects in platelet function is lacking in the literature, but factors impacting platelet function and coagulation pathways such as acquired von Willebrand factor syndrome, hyperviscosity, abnormal hematopoiesis, cryoglobulinemia and amyloidosis may contribute to bleeding. Understanding the pathophysiological mechanisms behind bleeding is important, as common WM therapies, including chemo-immunotherapy and Bruton's tyrosine kinase inhibitors, carry attendant bleeding risks. Furthermore, due to the relatively indolent nature of this lymphoma, most patients diagnosed with WM are often older and have one or more comorbidities, requiring treatment with anticoagulant or antiplatelet drugs. It is thus important to understand the origin of the WM bleeding phenotype, to better stratify patients according to their bleeding risk, and enhance confidence in clinical decisions regarding treatment management. In this review, we detail the evidence for various contributing factors to the bleeding phenotype in WM and focus on current and emerging diagnostic tools that will aid evaluation and management of bleeding in these patients.<\/jats:p>","DOI":"10.1055\/a-1896-7092","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T23:11:25Z","timestamp":1657581085000},"page":"1843-1857","source":"Crossref","is-referenced-by-count":13,"title":["Bleeding Propensity in Waldenstr\u00f6m Macroglobulinemia: Potential Causes and Evaluation"],"prefix":"10.1055","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7489-812X","authenticated-orcid":false,"given":"Simone A.","family":"Brysland","sequence":"additional","affiliation":[{"name":"Australian Cancer Research Foundation, Department of Cancer Biology and Therapeutics, John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5320-4707","authenticated-orcid":false,"given":"M. Gohar","family":"Maqbool","sequence":"additional","affiliation":[{"name":"Department of Haematology, Canberra Hospital, Canberra, Australian Capital Territory, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6766-8345","authenticated-orcid":false,"given":"Dipti","family":"Talaulikar","sequence":"additional","affiliation":[{"name":"Department of Haematology, Canberra Hospital, Canberra, Australian Capital Territory, Australia"},{"name":"College of Health and Medicine, The Australian National University, Canberra, Australian Capital Territory, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9453-9688","authenticated-orcid":false,"given":"Elizabeth E.","family":"Gardiner","sequence":"additional","affiliation":[{"name":"Australian Cancer Research Foundation, Department of Cancer Biology and Therapeutics, John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/imj.13311","article-title":"Treatment of patients with Waldenstr\u00f6m macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group","volume":"47","author":"D Talaulikar","year":"2017","journal-title":"Intern Med J"},{"issue":"03","key":"ref2","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1046\/j.1365-2141.2001.03144.x","article-title":"Waldenstr\u00f6m macroglobulinaemia: presenting features and outcome in a series with 217 cases","volume":"115","author":"R Garc\u00eda-Sanz","year":"2001","journal-title":"Br J Haematol"},{"issue":"06","key":"ref3","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2015-01-553974","article-title":"How I treat Waldenstr\u00f6m macroglobulinemia","volume":"126","author":"S P Treon","year":"2015","journal-title":"Blood"},{"issue":"16","key":"ref4","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.19.00394","article-title":"Progression risk stratification of asymptomatic Waldenstr\u00f6m macroglobulinemia","volume":"37","author":"M Bustoros","year":"2019","journal-title":"J Clin Oncol"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"eabl4644","DOI":"10.1126\/sciadv.abl4644","article-title":"Preneoplastic somatic mutations including MYD88\n          L265P in lymphoplasmacytic lymphoma","volume":"8","author":"S Rodriguez","year":"2022","journal-title":"Sci Adv"},{"issue":"17","key":"ref6","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood.2021012953","article-title":"Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenstr\u00f6m macroglobulinemia","volume":"138","author":"S P Treon","year":"2021","journal-title":"Blood"},{"issue":"09","key":"ref7","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m's macroglobulinemia","volume":"367","author":"S P Treon","year":"2012","journal-title":"N Engl J Med"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/leu.2012.257","article-title":"IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphomas","volume":"27","author":"N Gachard","year":"2013","journal-title":"Leukemia"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2012-09-454355","article-title":"MYD88 L265P in Waldenstr\u00f6m macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction","volume":"121","author":"L Xu","year":"2013","journal-title":"Blood"},{"issue":"13","key":"ref10","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1182\/blood-2012-09-457101","article-title":"Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms","volume":"121","author":"M Varettoni","year":"2013","journal-title":"Blood"},{"issue":"23","key":"ref11","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMc1211959","article-title":"MYD88 L265P somatic mutation in IgM MGUS","volume":"367","author":"O Landgren","year":"2012","journal-title":"N Engl J Med"},{"issue":"08","key":"ref12","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/leu.2013.62","article-title":"MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstr\u00f6m's macroglobulinemia","volume":"27","author":"C Jim\u00e9nez","year":"2013","journal-title":"Leukemia"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1038\/bcj.2014.4","article-title":"Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma","volume":"4","author":"S M Ansell","year":"2014","journal-title":"Blood Cancer J"},{"issue":"21","key":"ref14","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1182\/bloodadvances.2018022962","article-title":"Insights into the genomic landscape of MYD88 wild-type Waldenstr\u00f6m macroglobulinemia","volume":"2","author":"Z R Hunter","year":"2018","journal-title":"Blood Adv"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.pathol.2019.11.002","article-title":"A practical guide to laboratory investigations at diagnosis and follow up in Waldenstr\u00f6m macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group","volume":"52","author":"M G Maqbool","year":"2020","journal-title":"Pathology"},{"issue":"05","key":"ref16","first-page":"585","article-title":"Identification of 2 DNA methylation subtypes of Waldenstr\u00f6m macroglobulinemia with plasma and memory B-cell features","volume":"136","author":"D Roos-Weil","year":"2020","journal-title":"Blood"},{"issue":"07","key":"ref17","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/blood-2012-12-475111","article-title":"A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstr\u00f6m macroglobulinemia","volume":"122","author":"G Yang","year":"2013","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.12703\/P6-97","article-title":"MyD88: a central player in innate immune signaling","volume":"6","author":"J Deguine","year":"2014","journal-title":"F1000Prime Rep"},{"issue":"09","key":"ref19","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/leu.2014.88","article-title":"MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenstr\u00f6m's Macroglobulinemia","volume":"28","author":"O Landgren","year":"2014","journal-title":"Leukemia"},{"issue":"21","key":"ref20","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2019000588","article-title":"Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells","volume":"3","author":"T Sewastianik","year":"2019","journal-title":"Blood Adv"},{"issue":"07","key":"ref21","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1161\/ATVBAHA.120.314180","article-title":"Platelets endocytose viral particles and are activated via TLR (Toll-like receptor) signaling","volume":"40","author":"M Banerjee","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Z R Hunter","year":"2014","journal-title":"Blood"},{"issue":"06","key":"ref23","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1158\/1078-0432.CCR-15-0646","article-title":"Genomic landscape of CXCR4 mutations in Waldenstrom Macroglobulinemia","volume":"22","author":"S Poulain","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"15","key":"ref24","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia","volume":"372","author":"S P Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2174\/156652411795677963","article-title":"Clinical and genetic features of warts, hypogammaglobulinemia, infections and myelokathexis (WHIM) syndrome","volume":"11","author":"L Dotta","year":"2011","journal-title":"Curr Mol Med"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/leu.2014.187","article-title":"The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's macroglobulinemia","volume":"29","author":"Y Cao","year":"2015","journal-title":"Leukemia"},{"issue":"26","key":"ref27","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1182\/blood-2014-03-564583","article-title":"C1013G\/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma","volume":"123","author":"A M Roccaro","year":"2014","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.0954-6820.1944.tb03955.x","article-title":"Incipient myelomatosis or \u00abessential\u00ab hyperglobulinemia with fibrinogenopenia \u2014 a new syndrome?","volume":"117","author":"J Waldenstr\u00f6m","year":"1944","journal-title":"Acta Med Scand"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/asheducation-2004.1.257","article-title":"Amyloidosis and Waldenstr\u00f6m's macroglobulinemia","volume":"\u2022\u2022\u2022","author":"M A Gertz","year":"2004","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.critrevonc.2010.09.007","article-title":"Waldenstr\u00f6m's macroglobulinemia. An overview of its clinical, biochemical, immunological and therapeutic features and our series of 121 patients collected in a single center","volume":"80","author":"F Merchionne","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"issue":"04","key":"ref31","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-2007-976169","article-title":"Hemostatic dysfunction in paraproteinemias and amyloidosis","volume":"33","author":"M Zangari","year":"2007","journal-title":"Semin Thromb Hemost"},{"issue":"07","key":"ref32","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1016\/S2352-3026(18)30087-5","article-title":"Treatment and outcome patterns in European patients with Waldenstr\u00f6m's macroglobulinaemia: a large, observational, retrospective chart review","volume":"5","author":"C Buske","year":"2018","journal-title":"Lancet Haematol"},{"issue":"04","key":"ref33","first-page":"282","article-title":"Managing thrombocytopenia associated with cancer chemotherapy","volume":"29","author":"D J Kuter","year":"2015","journal-title":"Oncology (Williston Park)"},{"issue":"03","key":"ref34","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.4103\/jfmpc.jfmpc_972_19","article-title":"Waldenstrom's macroglobulinemia: a case report","volume":"9","author":"N Kolikkat","year":"2020","journal-title":"J Family Med Prim Care"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/978-1-4939-2095-2_13","article-title":"Structure and function of platelet receptors initiating blood clotting","volume":"844","author":"E E Gardiner","year":"2014","journal-title":"Adv Exp Med Biol"},{"issue":"06","key":"ref36","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.17219\/acem\/64942","article-title":"Acquired von Willebrand Syndrome","volume":"25","author":"A Mital","year":"2016","journal-title":"Adv Clin Exp Med"},{"issue":"02","key":"ref37","first-page":"345","article-title":"Acquired von Willebrand syndrome: data from an international registry","volume":"84","author":"A B Federici","year":"2000","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref38","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/bjh.15200","article-title":"Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenstr\u00f6m macroglobulinaemia","volume":"184","author":"J J Castillo","year":"2019","journal-title":"Br J Haematol"},{"issue":"08","key":"ref39","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.3324\/haematol.2020.255117","article-title":"Acquired von Willebrand syndrome: focused for hematologists","volume":"105","author":"M Franchini","year":"2020","journal-title":"Haematologica"},{"issue":"12","key":"ref40","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1002\/lt.20594","article-title":"High dose intravenous immunoglobulin treatment: mechanisms of action","volume":"11","author":"P Boros","year":"2005","journal-title":"Liver Transpl"},{"issue":"02","key":"ref41","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/rth2.12481","article-title":"Acquired von Willebrand syndrome in monoclonal gammopathy - a scoping review on hemostatic management","volume":"5","author":"M Y Abou-Ismail","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"06","key":"ref42","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00277-016-2650-x","article-title":"Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias","volume":"95","author":"C Dicke","year":"2016","journal-title":"Ann Hematol"},{"issue":"13","key":"ref43","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1016\/j.bpj.2021.05.013","article-title":"In silico biophysics and hemorheology of blood hyperviscosity syndrome","volume":"120","author":"E Javadi","year":"2021","journal-title":"Biophys J"},{"issue":"01","key":"ref44","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3816\/CLM.2009.n.026","article-title":"Waldenstr\u00f6m's macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia","volume":"9","author":"M J Stone","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"13","key":"ref45","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1182\/blood-2018-06-846816","article-title":"Acute hyperviscosity: syndromes and management","volume":"132","author":"M A Gertz","year":"2018","journal-title":"Blood"},{"issue":"04","key":"ref46","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1182\/blood.V80.4.953.953","article-title":"Role of plasma viscosity in platelet adhesion","volume":"80","author":"H F van Breugel","year":"1992","journal-title":"Blood"},{"issue":"05","key":"ref47","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.hoc.2018.05.008","article-title":"Initial evaluation of the patient with Waldenstr\u00f6m macroglobulinemia","volume":"32","author":"J J Castillo","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"issue":"09","key":"ref48","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1365-2362.2009.02177.x","article-title":"Mechanisms underlying acquired von Willebrand syndrome associated with an IgM paraprotein","volume":"39","author":"M Mayerhofer","year":"2009","journal-title":"Eur J Clin Invest"},{"issue":"04","key":"ref49","doi-asserted-by":"crossref","first-page":"571","DOI":"10.7326\/0003-4819-77-4-571","article-title":"An IgM circulating anticoagulant with factor VIII inhibitory activity","volume":"77","author":"E M McKelvey","year":"1972","journal-title":"Ann Intern Med"},{"issue":"03","key":"ref50","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/blood.V35.3.370.370","article-title":"A macroglobulin with inhibitory activity against coagulation factor VIII","volume":"35","author":"P A Castaldi","year":"1970","journal-title":"Blood"},{"issue":"03","key":"ref51","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/s-0038-1650099","article-title":"Acquired von Willebrand's syndrome in the course of Waldenstr\u00f6m's disease","volume":"44","author":"C Mazurier","year":"1980","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref52","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/(SICI)1096-8652(200003)63:3<145::AID-AJH7>3.0.CO;2-E","article-title":"Antibody studies of factor VIII inhibitor in a case with Waldenstr\u00f6m's macroglobulinemia","volume":"63","author":"T Endo","year":"2000","journal-title":"Am J Hematol"},{"issue":"02","key":"ref53","first-page":"173","article-title":"Acquired hemophilia in a patient with myeloma","volume":"160","author":"L S Loftus","year":"1994","journal-title":"West J Med"},{"issue":"11","key":"ref54","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1191\/0961203303lu463cr","article-title":"Coexistence of lupus anticoagulant and acquired haemophilia in a patient with monoclonal gammopathy of unknown significance","volume":"12","author":"A Taher","year":"2003","journal-title":"Lupus"},{"issue":"04","key":"ref55","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/ajh.2830240404","article-title":"Anti-platelet and anti-DNA IgM in Waldenstr\u00f6m macroglobulinemia and ITP","volume":"24","author":"L Varticovski","year":"1987","journal-title":"Am J Hematol"},{"issue":"02","key":"ref56","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/1096-8652(200102)66:2<116::AID-AJH1026>3.0.CO;2-V","article-title":"Autoimmune thrombocytopenia in Waldenstr\u00f6m's macroglobulinemia","volume":"66","author":"R G Owen","year":"2001","journal-title":"Am J Hematol"},{"issue":"10","key":"ref57","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1046\/j.1537-2995.1994.341095026980.x","article-title":"Waldenstr\u00f6m's macroglobulinemia with an IgM paraprotein that is both a cold agglutinin and a cryoglobulin and has a suppressive effect on progenitor cell growth","volume":"34","author":"M Zago-Novaretti","year":"1994","journal-title":"Transfusion"},{"issue":"03","key":"ref58","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3324\/haematol.2009.017251","article-title":"Pathophysiology of Waldenstr\u00f6m's macroglobulinemia","volume":"95","author":"M J Stone","year":"2010","journal-title":"Haematologica"},{"issue":"01","key":"ref59","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ehf2.13701","article-title":"Thromboembolism and bleeding in systemic amyloidosis: a review","volume":"9","author":"M Nicol","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"03","key":"ref60","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41375-018-0286-7","article-title":"Primary systemic amyloidosis in patients with Waldenstr\u00f6m macroglobulinemia","volume":"33","author":"S Zanwar","year":"2019","journal-title":"Leukemia"},{"issue":"05","key":"ref61","doi-asserted-by":"crossref","first-page":"3","DOI":"10.14309\/crj.0000000000000066","article-title":"Gastric amyloidosis causing nonvariceal upper gastrointestinal bleeding","volume":"6","author":"S Sundaram","year":"2019","journal-title":"ACG Case Rep J"},{"issue":"25","key":"ref62","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1056\/NEJM200106213442516","article-title":"Deep venous thrombosis and thalidomide therapy for multiple myeloma","volume":"344","author":"K Osman","year":"2001","journal-title":"N Engl J Med"},{"issue":"01","key":"ref63","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/13506129.2020.1810010","article-title":"Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding","volume":"28","author":"L R Mitrani","year":"2021","journal-title":"Amyloid"},{"issue":"04","key":"ref64","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3109\/13506129909007339","article-title":"Abnormalities in thrombin-antithrombin pathway in AL amyloidosis","volume":"6","author":"G Gamba","year":"1999","journal-title":"Amyloid"},{"issue":"01","key":"ref65","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3324\/haematol.2012.068155","article-title":"Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience","volume":"98","author":"A J Cowan","year":"2013","journal-title":"Haematologica"},{"issue":"01","key":"ref66","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.hemonc.2018.05.002","article-title":"Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease","volume":"12","author":"G Patel","year":"2019","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"03","key":"ref67","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/09537104.2020.1727871","article-title":"Novel scientific approaches and future research directions in understanding ITP","volume":"31","author":"S M Hicks","year":"2020","journal-title":"Platelets"},{"issue":"03","key":"ref68","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/jth.12813","article-title":"Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review","volume":"13","author":"C Neunert","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref69","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/ejh.12262","article-title":"An overview of platelet indices and methods for evaluating platelet function in thrombocytopenic patients","volume":"92","author":"P J Vinholt","year":"2014","journal-title":"Eur J Haematol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1146\/annurev-bioeng-062117-121215","article-title":"Platelet mechanotransduction","volume":"20","author":"C E Hansen","year":"2018","journal-title":"Annu Rev Biomed Eng"},{"issue":"01","key":"ref71","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/10739680802651477","article-title":"Platelet adhesion under flow","volume":"16","author":"Z M Ruggeri","year":"2009","journal-title":"Microcirculation"},{"issue":"01","key":"ref72","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/15216540310001649831","article-title":"Platelet interactions in thrombosis","volume":"56","author":"R K Andrews","year":"2004","journal-title":"IUBMB Life"},{"issue":"06","key":"ref73","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.healun.2015.12.024","article-title":"Longitudinal changes in hemostatic parameters and reduced pulsatility contribute to non-surgical bleeding in patients with centrifugal continuous-flow left ventricular assist devices","volume":"35","author":"K Muthiah","year":"2016","journal-title":"J Heart Lung Transplant"},{"issue":"12","key":"ref74","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1182\/bloodadvances.2020001776","article-title":"Loss of GPVI and GPIb\u03b1 contributes to trauma-induced platelet dysfunction in severely injured patients","volume":"4","author":"P Vulliamy","year":"2020","journal-title":"Blood Adv"},{"issue":"08","key":"ref75","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1182\/blood-2012-12-467415","article-title":"Low adhesion receptor levels on circulating platelets in patients with lymphoproliferative diseases before receiving Navitoclax (ABT-263)","volume":"121","author":"J Qiao","year":"2013","journal-title":"Blood"},{"issue":"04","key":"ref76","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/leu.2014.247","article-title":"Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation","volume":"29","author":"S Kamel","year":"2015","journal-title":"Leukemia"},{"issue":"11","key":"ref77","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1161\/ATVBAHA.121.316373","article-title":"Platelet heterogeneity in myeloproliferative neoplasms","volume":"41","author":"S Thomas","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"7835","DOI":"10.1038\/ncomms8835","article-title":"Thrombin-dependent intravascular leukocyte trafficking regulated by fibrin and the platelet receptors GPIb and PAR4","volume":"6","author":"Z S Kaplan","year":"2015","journal-title":"Nat Commun"},{"issue":"05","key":"ref79","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/blood-2015-02-629717","article-title":"Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation","volume":"126","author":"E Mammadova-Bach","year":"2015","journal-title":"Blood"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1126\/science.1083917","article-title":"Crystal structure of the GpIbalpha-thrombin complex essential for platelet aggregation","volume":"301","author":"J J Dumas","year":"2003","journal-title":"Science"},{"issue":"43","key":"ref81","first-page":"27183","article-title":"Networking in the hemostatic system. Integrin alphaiibbeta3 binds prothrombin and influences its activation","volume":"272","author":"T V Byzova","year":"1997","journal-title":"J Biol Chem"},{"key":"ref82","first-page":"890864","article-title":"Waldenstrom's macroglobulinemia and peripheral neuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes with a bleeding diathesis and rash","volume":"2013","author":"S Haider","year":"2013","journal-title":"Case Rep Oncol Med"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/978-0-387-79962-9_17","article-title":"Bleeding disorders associated with cancer dysproteinemias","volume":"148","author":"M Zangari","year":"2009","journal-title":"Cancer Treat Res"},{"issue":"05","key":"ref84","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/cancers10050147","article-title":"Bone marrow defects and platelet function: a focus on MDS and CLL","volume":"10","author":"S Luu","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"11","key":"ref85","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1016\/S2352-3026(20)30224-6","article-title":"Consensus treatment recommendations from the tenth International Workshop for Waldenstr\u00f6m Macroglobulinaemia","volume":"7","author":"J J Castillo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"10","key":"ref86","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"G Salles","year":"2017","journal-title":"Adv Ther"},{"issue":"11","key":"ref87","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1002\/cncr.20658","article-title":"Initial immunoglobulin M \u2018flare\u2019 after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study","volume":"101","author":"I M Ghobrial","year":"2004","journal-title":"Cancer"},{"issue":"04","key":"ref88","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ajh.21372","article-title":"Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon","volume":"84","author":"R Ram","year":"2009","journal-title":"Am J Hematol"},{"key":"ref89","first-page":"1","article-title":"Bendamustine: mechanism of action and clinical data","volume":"9","author":"B D Cheson","year":"2011","journal-title":"Clin Adv Hematol Oncol"},{"issue":"10","key":"ref90","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/jcm11102807","article-title":"Bruton's kinase inhibitors for the treatment of immunological diseases: current status and perspectives","volume":"11","author":"E Robak","year":"2022","journal-title":"J Clin Med"},{"issue":"05","key":"ref91","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/cancers13051103","article-title":"Bleeding by Bruton tyrosine kinase-inhibitors: dependency on drug type and disease","volume":"13","author":"P von Hundelshausen","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"08","key":"ref92","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood-2006-01-011817","article-title":"Bruton tyrosine kinase is essential for botrocetin\/VWF-induced signaling and GPIb-dependent thrombus formation in vivo","volume":"108","author":"J Liu","year":"2006","journal-title":"Blood"},{"issue":"12","key":"ref93","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1161\/ATVBAHA.110.207522","article-title":"Signaling during platelet adhesion and activation","volume":"30","author":"Z Li","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"ref94","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1182\/blood-2003-04-1142","article-title":"Tec regulates platelet activation by GPVI in the absence of Btk","volume":"102","author":"B T Atkinson","year":"2003","journal-title":"Blood"},{"issue":"11","key":"ref95","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.3109\/10428194.2013.777837","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)","volume":"54","author":"J A Burger","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"05","key":"ref96","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/jth.13651","article-title":"Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies","volume":"15","author":"J J Shatzel","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"26","key":"ref97","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions","volume":"124","author":"M Levade","year":"2014","journal-title":"Blood"},{"issue":"26","key":"ref98","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1182\/bloodadvances.2017011999","article-title":"Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib","volume":"1","author":"A P Bye","year":"2017","journal-title":"Blood Adv"},{"issue":"09","key":"ref99","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/jth.14225","article-title":"Acquired platelet antagonism: off-target antiplatelet effects of malignancy treatment with tyrosine kinase inhibitors","volume":"16","author":"B ME Tullemans","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"24","key":"ref100","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/bloodadvances.2019000640","article-title":"Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin \u03b1IIb\u03b23 in mice and humans","volume":"3","author":"G Dobie","year":"2019","journal-title":"Blood Adv"},{"issue":"04","key":"ref101","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/bjh.15690","article-title":"Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: an integrated analysis","volume":"184","author":"J R Brown","year":"2019","journal-title":"Br J Haematol"},{"issue":"07","key":"ref102","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.3324\/haematol.2017.186908","article-title":"Ibrutinib withdrawal symptoms in patients with Waldenstr\u00f6m macroglobulinemia","volume":"103","author":"J J Castillo","year":"2018","journal-title":"Haematologica"},{"issue":"04","key":"ref103","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ajh.25023","article-title":"Ibrutinib discontinuation in Waldenstr\u00f6m macroglobulinemia: etiologies, outcomes, and IgM rebound","volume":"93","author":"J N Gustine","year":"2018","journal-title":"Am J Hematol"},{"issue":"06","key":"ref104","doi-asserted-by":"crossref","first-page":"E312","DOI":"10.1002\/ajh.24366","article-title":"Atrial fibrillation associated with ibrutinib in Waldenstr\u00f6m macroglobulinemia","volume":"91","author":"J N Gustine","year":"2016","journal-title":"Am J Hematol"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.clml.2017.02.011","article-title":"Analysis of efficacy and tolerability of Bruton tyrosine kinase inhibitor ibrutinib in various B-cell malignancies in the general community: a single-center experience","volume":"17S","author":"N Ali","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"25","key":"ref106","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m's macroglobulinemia","volume":"378","author":"M A Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"02","key":"ref107","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","article-title":"Ibrutinib for patients with rituximab-refractory Waldenstr\u00f6m's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial","volume":"18","author":"M A Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"27","key":"ref108","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2018.78.6426","article-title":"Ibrutinib monotherapy in symptomatic, treatment-naive patients with Waldenstrom macroglobulinemia","volume":"36","author":"S P Treon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"04","key":"ref109","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.amjcard.2019.05.029","article-title":"Rates and risk of atrial arrhythmias in patients treated with ibrutinib compared with cytotoxic chemotherapy","volume":"124","author":"M G Fradley","year":"2019","journal-title":"Am J Cardiol"},{"issue":"03","key":"ref110","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.16168","article-title":"Ibrutinib monotherapy outside of clinical trial setting in Waldenstr\u00f6m macroglobulinaemia: practice patterns, toxicities and outcomes","volume":"188","author":"J P Abeykoon","year":"2020","journal-title":"Br J Haematol"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1309\/LM749BQETKYPYPVM","article-title":"Pre-analytical variables in coagulation testing associated with diagnostic errors in hemostasis","volume":"43","author":"E J Favaloro","year":"2012","journal-title":"Lab Med"},{"issue":"01","key":"ref112","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1182\/hematology.2019000064","article-title":"New advances in the diagnosis of von Willebrand disease","volume":"2019","author":"R Sharma","year":"2019","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"03","key":"ref113","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/hae.13957","article-title":"Comparative assessment of von Willebrand factor multimers vs activity for von Willebrand disease using modern contemporary methodologies","volume":"26","author":"E J Favaloro","year":"2020","journal-title":"Haemophilia"},{"issue":"10","key":"ref114","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1055\/a-1806-9972","article-title":"HemosIL VWF:GPIbR assay has a greater sensitivity than VWF:RCo technique to detect acquired von Willebrand syndrome in myeloproliferative neoplasms","volume":"122","author":"P Laporte","year":"2022","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref115","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11239-021-02621-1","article-title":"Global coagulation assays in hypercoagulable states","volume":"54","author":"H Y Lim","year":"2022","journal-title":"J Thromb Thrombolysis"},{"issue":"05","key":"ref116","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/jth.15287","article-title":"Recommendations for the measurement of thrombin generation: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"19","author":"M Ninivaggi","year":"2021","journal-title":"J Thromb Haemost"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"679934","DOI":"10.3389\/fcvm.2021.679934","article-title":"Thrombin generation as a method to identify the risk of bleeding in high clinical-risk patients using dual antiplatelet therapy","volume":"8","author":"C PDM de Breet","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"04","key":"ref118","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2516.2005.01107.x","article-title":"Thrombin generation and phenotypic correlation in haemophilia A","volume":"11","author":"C P Beltr\u00e1n-Miranda","year":"2005","journal-title":"Haemophilia"},{"issue":"03","key":"ref119","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.thromres.2007.04.012","article-title":"The endogenous thrombin potential and the risk of venous thromboembolism","volume":"121","author":"A Tripodi","year":"2007","journal-title":"Thromb Res"},{"issue":"12","key":"ref120","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1055\/a-1450-8300","article-title":"Added value of blood cells in thrombin generation testing","volume":"121","author":"J Wan","year":"2021","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref121","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1080\/09537104.2018.1475636","article-title":"An update on quality control for the PFA-100\/PFA-200","volume":"29","author":"E J Favaloro","year":"2018","journal-title":"Platelets"},{"issue":"12","key":"ref122","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1515\/cclm-2019-0380","article-title":"The role of platelets in bleeding in patients with thrombocytopenia and hematological disease","volume":"57","author":"P J Vinholt","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/VHRM.S44469","article-title":"Platelet function tests: a comparative review","volume":"11","author":"R Paniccia","year":"2015","journal-title":"Vasc Health Risk Manag"},{"issue":"01","key":"ref124","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/09537104.2017.1371290","article-title":"Screening for platelet function disorders with Multiplate and platelet function analyzer","volume":"30","author":"F CJI Moenen","year":"2019","journal-title":"Platelets"},{"issue":"S 06","key":"ref125","first-page":"S86","article-title":"Viscoelastic testing in oncology patients (including for the diagnosis of fibrinolysis): review of existing evidence, technology comparison, and clinical utility","volume":"60","author":"M Walsh","year":"2020","journal-title":"Transfusion"},{"issue":"06","key":"ref126","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.amjsurg.2019.09.024","article-title":"Platelet dysfunction on thromboelastogram is associated with severity of blunt traumatic brain injury","volume":"218","author":"A B Kay","year":"2019","journal-title":"Am J Surg"},{"issue":"04","key":"ref127","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1160\/TH11-10-0745","article-title":"Focusing on plasma glycoprotein VI","volume":"107","author":"M Al-Tamimi","year":"2012","journal-title":"Thromb Haemost"},{"issue":"12","key":"ref128","first-page":"20","article-title":"Novel stenotic microchannels to study thrombus formation in shear gradients: influence of shear forces and human platelet-related factors","volume":"20","author":"M Lui","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"03","key":"ref129","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/jth.14717","article-title":"In vitro flow based systems to study platelet function and thrombus formation: recommendations for standardization: Communication from the SSC on Biorheology of the ISTH","volume":"18","author":"P H Mangin","year":"2020","journal-title":"J Thromb Haemost"},{"key":"ref130","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1038\/ncomms5257","article-title":"Identification of platelet function defects by multi-parameter assessment of thrombus formation","volume":"5","author":"S M de Witt","year":"2014","journal-title":"Nat Commun"},{"issue":"15","key":"ref131","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1182\/blood-2012-04-416594","article-title":"The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways","volume":"120","author":"J M Burkhart","year":"2012","journal-title":"Blood"},{"issue":"04","key":"ref132","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1042\/BST20150113","article-title":"Role of chemokine receptors CXCR4 and CXCR7 for platelet function","volume":"43","author":"M Chatterjee","year":"2015","journal-title":"Biochem Soc Trans"},{"issue":"16","key":"ref133","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2011-11-388256","article-title":"Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia","volume":"120","author":"B Hivert","year":"2012","journal-title":"Blood"},{"issue":"01","key":"ref134","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clml.2018.07.294","article-title":"Elevated vWF antigen serum levels are associated with poor prognosis, and decreased circulating ADAMTS-13 antigen levels are associated with increased IgM levels and features of WM but not increased vWF levels in patients with symptomatic WM","volume":"19","author":"M Gavriatopoulou","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"03","key":"ref135","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/MBC.0000000000000065","article-title":"Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis","volume":"25","author":"M Stockschlaeder","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"01","key":"ref136","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jth.12412","article-title":"Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII","volume":"12","author":"T Shahani","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref137","first-page":"EREP02","article-title":"The factor VIII\/von Willebrand factor complex: basic and clinical issues","volume":"88","author":"A B Federici","year":"2003","journal-title":"Haematologica"},{"key":"ref138","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000208493","article-title":"A study of haemostasis in macroglobulinaemia","volume":"47","author":"A K Saraya","year":"1972","journal-title":"Acta Haematol"},{"issue":"02","key":"ref139","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000207751","article-title":"Platelet functions in dysproteinaemia","volume":"59","author":"J Kasturi","year":"1978","journal-title":"Acta Haematol"},{"issue":"23","key":"ref140","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1182\/blood-2010-09-307306","article-title":"Tissue factor expression on platelets is a dynamic event","volume":"116","author":"M Camera","year":"2010","journal-title":"Blood"},{"issue":"04","key":"ref141","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/09537100220146398","article-title":"The presence and release of tissue factor from human platelets","volume":"13","author":"F A Siddiqui","year":"2002","journal-title":"Platelets"},{"key":"ref142","doi-asserted-by":"crossref","first-page":"630942","DOI":"10.3389\/fcell.2021.630942","article-title":"Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects","volume":"9","author":"H Y Estupi\u00f1\u00e1n","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"ref143","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood-2018-99-109973","article-title":"Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies","volume":"132","author":"A Kaptein","year":"2018","journal-title":"Blood"},{"issue":"02","key":"ref144","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/10428194.2013.803226","article-title":"Ibrutinib in chronic lymphocytic leukemia and B cell malignancies","volume":"55","author":"J R Brown","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"05","key":"ref145","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1182\/blood.V35.5.695.695","article-title":"Hemostatic defects in dysproteinemias","volume":"35","author":"H A Perkins","year":"1970","journal-title":"Blood"},{"issue":"02","key":"ref146","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1053\/sonc.2003.50064","article-title":"Prognostic factors in symptomatic Waldenstrom's macroglobulinemia","volume":"30","author":"G Merlini","year":"2003","journal-title":"Semin Oncol"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1896-7092.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:13:10Z","timestamp":1667347990000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1896-7092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":146,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11,1]]},"published-print":{"date-parts":[[2022,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1896-7092","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,11]]},"published":{"date-parts":[[2022,7,11]]}}}